Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions' stock price has been impacted by several events. Positive impacts included exceeding Q3 2025 earnings guidance, receiving an order from the U.S. Department of War for BioThrax®, FDA approval for Narcan multipacks, securing contracts for smallpox medical countermeasures, and a partnership with British Columbia for Naloxone Program. Negative impacts included a lawsuit against the former CEO for insider trading, a Q4 2025 revenue miss and decline in NARCAN revenue leading to a stock plunge, and analysts decreasing the company's price target. The company also announced an equity buyback program. Over the past year, Emergent BioSolutions' share price increased by 98.36%.

Demand seasonality for Emergent BioSolutions' products and services varies. Naloxone product sales can be impacted by temporary disruptions, but there is an expected growing demand. Medical countermeasure demand is influenced by the timing of government deliveries and funding availability. CDMO service demand is influenced by the biopharmaceutical industry's pipeline and government initiatives, but the company has been restructuring its Bioservices business.

Emergent BioSolutions, Inc. is a life sciences company focused on preparedness and response solutions for public health threats, operating in the biotechnology and specialty & generic drug manufacturing industries. Its products include commercial products like NARCAN® and KLOXXADO® Nasal Sprays, medical countermeasures (MCM) such as ACAM2000® and BioThrax®, and contract development and manufacturing (CDMO) services.

Emergent BioSolutions operates in the United States, Canada, and internationally, with the majority of its revenue derived from the United States. Key locations include Gaithersburg, Maryland (corporate office and R&D); Canton and Lansing, Michigan (manufacturing); Plymouth Meeting (Sales & Marketing); Washington, D.C. (Corporate Affairs); and Winnipeg, Canada (manufacturing, R&D, and corporate functions).

Emergent BioSolutions' brand reputation has been influenced by legal and regulatory scrutiny from past manufacturing issues, alongside efforts to highlight its public health contributions. Insider trading allegations against the former CEO and past manufacturing issues have negatively impacted its reputation. However, the company's focus on public health contributions, such as contracts for medical countermeasures and partnerships to expand access to NARCAN®, have positively contributed to its reputation.

Emergent BioSolutions' ownership is largely concentrated among institutional investors, who hold 78.63% of shares outstanding. Fuad El-Hibri, the company's founder, is the largest individual shareholder, owning 49.71% of the company. CEO Joseph C. Papa owns 0.7% of the company's shares, and insiders collectively hold 6.00% of the stock.